Delayed Graft Function

8
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
6
Early DiscoveryClinical DevelopmentMarket

On Market (4)

Approved therapies currently available

U
AZASANApproved
azathioprine
Unknown Company
Purine Antimetabolite [EPC]oral1999
U
AZATHIOPRINEApproved
azathioprine
Unknown Company
Purine Antimetabolite [EPC]oral1996
Apellis Pharmaceuticals
EMPAVELIApproved
pegcetacoplan
Apellis Pharmaceuticals
Complement Inhibitor [EPC]subcutaneous2021
Apellis Pharmaceuticals
SYFOVREApproved
pegcetacoplan
Apellis Pharmaceuticals
Complement Inhibitor [EPC]intravitreal2023

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
2 programs
1
azathioprinePhase 41 trial
Role of T Helper 17 and Regulatory T Cells in Delayed Graft FunctionN/A1 trial
Active Trials
NCT01232816Unknown50Est. Dec 2019
NCT00321906Completed181Est. Aug 2011
Apellis Pharmaceuticals
Apellis PharmaceuticalsAustralia - Hawthorn East
1 program
1
1
PegcetacoplanPhase 31 trial
Active Trials
NCT07020832Recruiting320Est. Aug 2028
Veloxis Pharmaceuticals
1 program
1
Envarsus XRPhase 41 trial
Active Trials
NCT03864926CompletedEst. Jul 2022
argenx
argenxBelgium - Zwijnaarde
1 program
1
ARGX-117Phase 21 trial
Active Trials
NCT05907096Active Not Recruiting103Est. Jul 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Veloxis PharmaceuticalsEnvarsus XR
Astellasazathioprine
Apellis PharmaceuticalsPegcetacoplan
argenxARGX-117
AstellasRole of T Helper 17 and Regulatory T Cells in Delayed Graft Function

Clinical Trials (5)

Total enrollment: 654 patients across 5 trials

NCT03864926Veloxis PharmaceuticalsEnvarsus XR

Envarsus in Delayed Graft Function (E-DGF)

Start: Mar 2019Est. completion: Jul 2022
Phase 4Completed
NCT00321906Astellasazathioprine

Comparison of Sirolimus and Azathioprine in Lung Transplantation

Start: Apr 2002Est. completion: Aug 2011181 patients
Phase 4Completed
NCT07020832Apellis PharmaceuticalsPegcetacoplan

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Start: Feb 2026Est. completion: Aug 2028320 patients
Phase 3Recruiting
NCT05907096argenxARGX-117

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

Start: Feb 2024Est. completion: Jul 2026103 patients
Phase 2Active Not Recruiting
NCT01232816AstellasRole of T Helper 17 and Regulatory T Cells in Delayed Graft Function

Role of T Helper 17 and Regulatory T Cells in Delayed Graft Function

Start: Jul 2010Est. completion: Dec 201950 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 654 patients
4 companies competing in this space